Provider review
HealthRX review: it names the trials and says their results cannot predict yours
HealthRX distinguishes compounded products from the approved medicines tested in major trials. Its current homepage also uses a 25% weight-loss headline with an 88-week branded-tirzepatide footnote, so our earlier description of no percentage claims is historical. Before buying, separate the evidence claim from the plan’s upfront payment, pharmacy and refund terms.
Partner link — we may earn a commission. How we’re paid
Visit HealthRXOf HealthRX’s 2 dated product claims documented below, 2 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $190 for 30 days (Compounded semaglutide, one month bought outright). A matching claim does not mean the compounded product was tested or FDA-approved.
Names the trial for both molecules, quotes no figure from either, and says plainly that the trials tested a different product whose averages cannot predict yours. The most careful claim set among the sellers we compared it with.
Worth trusting if
- You want the study behind the medication named, with the paper listed
- You would rather be told a trial average cannot predict your result than be promised one
- You want a seller that states what kind of pharmacy makes your medication
Be skeptical if
- You want the pharmacy named rather than described, because this one is not
- You want to check its claim about rival clinics, because it names none of them
- You want a company you can identify — the terms name none
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at HealthRX
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $149 for the first month on the monthly Subscribe & Save plan, then $165 a month; a single month bought outright is $190, and the $99 a month is a year paid up front.
- Compounded tirzepatide injection — $193 for the first month on the monthly Subscribe & Save plan, then $214 a month; a single month bought outright is $239, and $179 a month on a year paid up front.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not HealthRX's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from HealthRX’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“How much weight can I expect to lose on semaglutide? STEP 1 studied a specific once-weekly injectable semaglutide product, not the compounded preparation offered here. Its average results cannot predict your response. Your clinician reviews treatment goals, progress, and tolerability with you.”
Read on the HealthRX site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. Reported a mean weight reduction of about 15% against about 2% on placebo. HealthRX names the trial and its NEJM paper and deliberately quotes none of its figures.
This is the claim a compounded seller should make, and almost none do. HealthRX names the right trial for the molecule, lists the paper, and then declines to borrow its result: it says STEP 1 tested a specific branded product rather than the compounded preparation it sells, and that an average from that trial cannot predict what happens to you. Every statement on the page is true, and the one caveat that applies to every compounded product on this site is one HealthRX states itself. Its homepage card goes the same way, describing the product as prepared by a licensed 503A pharmacy under a prescription and "Not FDA-approved" in a single sentence.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“The SURMOUNT-1 trial studied a specific once-weekly injectable tirzepatide product, not the compounded preparation offered here. Its average results cannot predict your response. … A receptor mechanism alone does not predict an individual result or establish equivalence between different preparations.”
Read on the HealthRX site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. Reported a mean reduction of roughly 21% at the top dose. HealthRX names the trial and does not quote the figure.
Same discipline as the semaglutide page. HealthRX names SURMOUNT-1, says it tested a different product, and says its average cannot predict your response. It adds a line most sellers would never write about their own product: that the mechanism "alone does not predict an individual result or establish equivalence between different preparations." The one superlative on the site sits on the pricing page, where tirzepatide is described as "a dual GIP and GLP-1 agonist with the largest average weight loss recorded in a phase-3 obesity trial." That is accurate for an approved medicine in this class and properly scoped to phase-3 obesity trials, and it describes the molecule rather than promising a result from the compounded preparation.2
Dispensing chain
Who actually fills your prescription
Read the full account
HealthRX states the tier and not the name. Every plan says the prescription is filled by a US-licensed pharmacy that makes the drug to order, and the homepage badges it alongside USP-797 — which is the compounding standard for sterile preparations, a description of how a pharmacy is supposed to work rather than a certificate anyone can look up. No pharmacy, address or license number is published, and no clinician is named at any level. Two things partly offset that. Its LegitScript certificate number is printed on the site and resolves to this domain when checked. And its terms say you may direct the prescription to a pharmacy of your own choosing, which is a genuine freedom and one almost nobody here offers.
Read on the HealthRX site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. What HealthRX offers instead of test data is unusually honest arithmetic: a pricing table with a column showing what each plan renews at, renewals that cost less than the first term, and a comparison against other clinics that carries a date and a stated basis while naming none of them. Its LegitScript certificate number is published and resolves to this domain, which proves a certificate was issued rather than anything about what arrives in the box. The USP-797 badge is a standard rather than an accreditation and should not be read as a third-party audit.
Read on the HealthRX site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
HealthRX publishes no list of states and makes no fifty-state claim, checked in September 2026 across the homepage, the pricing page and the terms. Its terms resolve disputes under California law, which says where it would argue rather than where it will ship.
Read the full licensing claim
No operating company is named beyond the brand — the terms choose California law and JAMS arbitration without identifying an entity, a registered address or a state of incorporation. No clinician is named either, though the site does commit to a licensed clinician's review typically within about a day.
Read on the HealthRX site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- It names STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, and lists the published papers on each product page.
- It says outright that both trials tested a specific branded product rather than the compounded preparation it sells, and that their averages cannot predict your response.
- The September product-page check found no weight-loss percentage for either compounded product; the current homepage does publish a 25% headline with a branded-trial footnote.
Show 8 more
- Its one superlative about tirzepatide is properly scoped to phase-3 obesity trials rather than claimed universally.
- The homepage cards describe the product as "Not FDA-approved" in the same sentence that describes it.
- It states that the medication is made to order under a prescription, rather than leaving the question open.
- Its LegitScript certificate number is printed on the site and resolves to this domain.
- Its terms let you send the prescription to a pharmacy of your own choosing.
- It publishes what every plan renews at, and renewals cost less than the first term.
- A full refund if a provider does not approve you, stated as part of every plan.
- No FDA warning letter.
- No pharmacy is named — the tier is stated and the facility is not.
- Its USP-797 badge is a compounding standard, not an accreditation anyone can look up.
- No company is named in its terms, which choose California law without identifying an entity.
Show 4 more
- No clinician is named — no prescriber, no medical director, no advisory panel.
- Its comparison against other clinics gives a date and a basis and names none of them.
- Its sermorelin, NAD+ and other products carry no trial reference we could grade.
- The $99 headline needs a year paid up front; month to month, semaglutide is $149 for the first month and $165 after that.
Verdict
The bottom line
If you want to know what an honest compounded GLP-1 page looks like, this is the one to compare the rest against. It names the study, lists the paper, and tells you the trial tested a different product whose average cannot predict yours. What it still will not tell you is which pharmacy fills your prescription or which company you are buying from, and those are the two questions we would put to it before ordering.
Opens HealthRX's website. A link is not a recommendation to take anything.
Payment comes before the clinical decision
The October 13 homepage describes buying a plan before completing the health intake, with a full refund if the clinician declines treatment. It separately states that dispensed prescription medicine cannot be returned. Those are different situations: a refund for ineligibility does not mean a used or dispatched order is refundable. 3
The site promises roughly 24-hour clinical review and overnight shipping after approval; neither is a guaranteed time from purchase to delivery. Confirm the dispensing pharmacy, actual order total and refill deadline before paying. The current homepage also uses a 25% headline, footnoted to an 88-week branded-tirzepatide trial. That corrects our earlier site-wide absence claim; it does not establish outcomes for a compounded prescription. The older price records and evidence analysis below retain their original verification dates.
Full analysis — 7 more sectionsCheck the claim · Why that's remarkable · The superlative, scoped · What it says about stopping · What it still won't tell you · The caveat it states itself · What it costs
Check the claim
HealthRX's semaglutide page, answering "How much weight can I expect to lose on semaglutide?":
"STEP 1 studied a specific once-weekly injectable semaglutide product, not the compounded preparation offered here. Its average results cannot predict your response."
Its tirzepatide page:
"The SURMOUNT-1 trial studied a specific once-weekly injectable tirzepatide product, not the compounded preparation offered here. Its average results cannot predict your response."
Both statements are true. STEP 1 randomized 1,961 adults to the manufacturer's semaglutide and reported a mean reduction of about 15% at 68 weeks. 1 SURMOUNT-1 randomized 2,539 to the manufacturer's tirzepatide and reported roughly 21% at the top dose at 72 weeks. 2 HealthRX lists both papers on the product pages and quotes neither figure.
The homepage cards follow suit: "Compounded semaglutide prepared by a licensed 503A pharmacy under a prescription written for you. Not FDA-approved."
Why that's remarkable
It shouldn't be. But here is what the same month produced from other sellers we graded:
- One named these exact two trials and then placed their results at month six.
- Two others promised 18% by week 24, on a screen you only reach after handing over your home address.
- A fourth published five statistics under a heading reading "clinical data" and sourced none of them.
HealthRX shows how little it takes to get this right: name the trial, say what it tested, and do not sell its average as your result.
The superlative, scoped
The one strong claim on the site is on the pricing page:
"…a dual GIP and GLP-1 agonist with the largest average weight loss recorded in a phase-3 obesity trial."
Note the scoping. Not "the largest ever", but the largest recorded in a phase-3 obesity trial, which is accurate for an approved medicine in this class. 2 It describes the molecule, and the tirzepatide page adds that a receptor mechanism "alone does not predict an individual result or establish equivalence between different preparations."
What it says about stopping
The homepage also answers the question most sellers skip: "Roughly two-thirds of lost weight returns within 12 months of discontinuing semaglutide in published extension data." HealthRX labels it as the STEP 1 extension. Putting weight regain in front of a buyer before checkout is a choice few sellers make.
What it still won't tell you
Two things.
Which pharmacy. HealthRX says the medication is made to order by a US-licensed pharmacy and badges USP-797 — which is the standard sterile compounding is supposed to follow, not a certificate a facility is awarded. No pharmacy name, no address, no license number.
Which company. Its terms choose California law and JAMS arbitration and never identify the business behind the site.
Against that, its LegitScript certificate number is published in the footer and resolves to this domain, and its terms say you may direct the prescription to a pharmacy of your own choosing — a freedom almost nobody in this market offers.
The caveat it states itself
Both trials tested the manufacturers' approved medicines. HealthRX sells compounded versions, made to order, not FDA-approved, and never compared with the approved product in a trial.
That is true of nearly every seller on this site. What sets HealthRX apart is that it says so on the product page, in the answer to the question buyers ask most.
What it costs
Month to month, compounded semaglutide is $149 for the first month on the Subscribe & Save plan and $165 a month after that; tirzepatide is $193 and then $214. Prepaid plans bring semaglutide to $99 a month and tirzepatide to $179 a month on a year paid up front, and the pricing table prints what every plan renews at.
Questions
Frequently asked questions
What does HealthRX claim about weight loss?
Almost nothing, on purpose. It names the right trial for each molecule, STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, lists the papers, and then says each trial studied a specific branded product rather than its compounded preparation and that the trial's average results cannot predict your response. It prints no weight-loss percentage for either product. It is the most careful claim set we have graded.
Is tirzepatide's trial result really the largest?
For an approved medicine in this class, yes. HealthRX's pricing page describes tirzepatide as having "the largest average weight loss recorded in a phase-3 obesity trial," which scopes the claim properly rather than claiming an outright record. SURMOUNT-1 reported roughly 21% at the top dose over 72 weeks, which is above what semaglutide achieved in STEP 1.
Do those trials apply to compounded medication?
Only in part, and HealthRX says so itself. Both trials tested the manufacturers' approved products, not compounded versions made to order by a pharmacy, and nothing published compares the two. HealthRX's product pages state that the trials studied a different product and that their averages cannot predict your response.
Which pharmacy makes it?
HealthRX doesn't name one. It does say the medication is made to order under a prescription by a US-licensed pharmacy, and badges USP-797 — which is the standard sterile compounding should follow rather than an accreditation you can look up. Its terms do let you send the prescription to a pharmacy of your own choosing.
What does it cost?
Compounded semaglutide is $149 for the first month on the monthly Subscribe & Save plan, then $165 a month; tirzepatide is $193, then $214. A single month bought outright is $190 for semaglutide, and the advertised $99 a month is a year paid up front. Unusually, its pricing table also prints what each plan renews at, and the renewals are cheaper than the first term.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
- USP-797
- The US Pharmacopeia chapter setting standards for compounding sterile preparations. It describes how a pharmacy should work, and is not a certificate awarded to a named facility.
- 503A
- A pharmacy that makes a drug to order for one named patient with a prescription. What it produces is not FDA-approved, and the FDA has not evaluated its safety, effectiveness or quality.
Compare
Others selling what HealthRX sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists HealthRX is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off HealthRX's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, roughly 21% mean reduction at the top dose reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Public buyer information checked October 13, 2026. Public primary source. the HealthRX site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.